Efficacy and Safety of Canagliflozin, a Sodium-Glucose Cotransporter 2 Inhibitor, as Add-on to Insulin in Patients With Type 1 Diabetes.

There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

Abstract

This study assessed the efficacy and safety of canagliflozin, a sodium-glucose cotransporter 2 inhibitor, as add-on to insulin in adults with type 1 diabetes.

Related collections

Author and article information

Journal

Journal ID (iso-abbrev): Diabetes Care

Title: Diabetes care

ISSN (Electronic): 1935-5548

ISSN (Print): 0149-5992

Publication date (Electronic): Dec 2015

Volume: 38

Issue: 12

Affiliations

[1 ] Center for Metabolic Research, VA San Diego Healthcare System, San Diego, CA University of California, San Diego, La Jolla, CA rrhenry@outlook.com.

[2 ] Janssen Research & Development, LLC, Raritan, NJ.

[3 ] Janssen Research & Development, LLC, San Diego, CA.

Article

Publisher Item ID: dc15-1730

DOI: 10.2337/dc15-1730

PubMed ID: 26486192

SO-VID: afd7761f-98e4-4f24-914c-b7a67b8eb89e

History

Data availability:

Comments

Comment on this article

scite_

Cited by 103

See all cited by